Next Article in Journal
The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities
Previous Article in Journal
Tau Protein in Lung Smooth Muscle Cells
Review

SARS-CoV-2 Spike Protein and Lung Vascular Cells

1
Department of Biochemistry and Molecular & Cell Biology, Georgetown University Medical Center, Washington, DC 20007, USA
2
Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA
*
Author to whom correspondence should be addressed.
J. Respir. 2021, 1(1), 40-48; https://doi.org/10.3390/jor1010004
Received: 11 December 2020 / Revised: 22 December 2020 / Accepted: 29 December 2020 / Published: 31 December 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the current pandemic of coronavirus disease 2019 (COVID-19), and COVID-19 vaccines focus on its spike protein. However, in addition to facilitating the membrane fusion and viral entry, the SARS-CoV-2 spike protein promotes cell growth signaling in human lung vascular cells, and patients who have died of COVID-19 have thickened pulmonary vascular walls, linking the spike protein to a fatal disease, pulmonary arterial hypertension (PAH). In addition to SARS-CoV spike proteins, gp120, the viral membrane fusion protein of human immunodeficiency virus (HIV), has been reported to promote cell signaling, and long-term surviving HIV-positive patients have a high incidence of developing PAH. This article describes the findings of the SARS-CoV-2 spike protein affecting lung vascular cells and explains how the spike protein possibly increases the incidence of PAH. Since the SARS-CoV-2 spike protein will be administered to millions of people as COVID-19 vaccines, it is critical to understand the biological effects of this protein on human cells to ensure that it does not promote long-term adverse health consequences. View Full-Text
Keywords: cell signaling; coronavirus; COVID-19; lung; pulmonary hypertension; SARS-CoV-2; spike protein; vaccine; vascular; viral membrane fusion protein cell signaling; coronavirus; COVID-19; lung; pulmonary hypertension; SARS-CoV-2; spike protein; vaccine; vascular; viral membrane fusion protein
Show Figures

Figure 1

MDPI and ACS Style

Suresh, S.J.; Suzuki, Y.J. SARS-CoV-2 Spike Protein and Lung Vascular Cells. J. Respir. 2021, 1, 40-48. https://doi.org/10.3390/jor1010004

AMA Style

Suresh SJ, Suzuki YJ. SARS-CoV-2 Spike Protein and Lung Vascular Cells. Journal of Respiration. 2021; 1(1):40-48. https://doi.org/10.3390/jor1010004

Chicago/Turabian Style

Suresh, Sri J., and Yuichiro J. Suzuki. 2021. "SARS-CoV-2 Spike Protein and Lung Vascular Cells" Journal of Respiration 1, no. 1: 40-48. https://doi.org/10.3390/jor1010004

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop